Cantor Fitzgerald Increases Earnings Estimates for Curis

Curis, Inc. (NASDAQ:CRIS) – Research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Curis in a research report issued on Thursday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biotechnology company will earn ($2.24) per share for the year, up from their prior estimate of ($2.37). The consensus estimate for Curis’ current full-year earnings is ($7.12) per share. Cantor Fitzgerald also issued estimates for Curis’ FY2026 earnings at ($0.99) EPS.

Curis (NASDAQ:CRIS) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.13. The company had revenue of $3.18 million for the quarter, compared to analyst estimates of $2.86 million.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $17.00.

Curis Stock Performance

Shares of CRIS opened at $1.23 on Monday. Curis has a 1 year low of $1.02 and a 1 year high of $4.70. The stock has a market capitalization of $15.90 million, a PE ratio of -0.25 and a beta of 3.88. The stock has a 50-day simple moving average of $1.55 and a 200-day simple moving average of $1.81.

Hedge Funds Weigh In On Curis

Hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in Curis during the first quarter worth approximately $27,000. Warberg Asset Management LLC acquired a new stake in Curis during the 3rd quarter worth $73,000. Squarepoint Ops LLC lifted its position in Curis by 17.9% in the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 8,973 shares during the last quarter. Focused Wealth Management Inc boosted its stake in Curis by 33.8% in the third quarter. Focused Wealth Management Inc now owns 79,199 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 19,995 shares in the last quarter. Finally, CM Management LLC grew its holdings in shares of Curis by 9.1% during the first quarter. CM Management LLC now owns 240,000 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 20,000 shares during the last quarter. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.